However, although CerK can be a potential target to contrast tumor cell proliferation and migration in both cell subtypes, siRNA- or NVP-231-mediated CerK inhibition showed that CerK could play different roles in more aggressive metastatic BC cell lines with respect to non-metastatic cell lines. Here, CERK is linked to breast cancer.